ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	9/11/2015 8:46:02 AM
	Read Replies (1) of 4474

ESMO abstracts available online...briga PFS in CNS is now 22.3m, more than double alectinib's 10.3m, but ORR is lower (53% vs. 57%). europeancancercongress.org Poster number P313 Conclusions: Brigatinib has promising antitumor activity in ALK+ NSCLC pts with intracranial CNS metastases, as suggested by the 53% intracranial ORR in pts with measurable lesions and the 22.3-mo median intracranial PFS. A prospective evaluation of brigatinib in ALK+ NSCLC pts with intracranial CNS metastases is under way as part of a separate, pivotal phase 2 trial (ALTA: ALK in Lung Cancer Trial of AP26113).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next